Targets › MPL
7 programs from 7 companies in 39 trials: 23 Phase 2, 7 Phase 4, 6 Phase 3, 3 Phase 1; Hematology, Oncology, Other; next expected readout Dec 2026.
Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K. In turn, These signaling cascades lead to the proliferation, survival, and differentiation of…. (UniProt, P40238)
Open in Phaseline: the race on MPL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Al-Mustansiriyah University | Avatrombopag Thrombopoietin receptor agonist | MPL | Phase 4 | ITP - Immune Thrombocytopenia | Jul 2027 |
| Amgen | Romiplostim Thrombopoietin receptor agonist | MPL | Phase 3 | Chemotherapy-induced Thrombocytopenia; Primary Immune Thrombocytopenia; CTIT: Cancer Therapy Induced Thrombocytopenia; Solid Tumors … | Feb 2027 |
| Jiangsu HengRui Medicine | Hetrombopag Olamine Thrombopoietin receptor agonist | MPL | Phase 3 | Chemotherapy-Induced Thrombocytopenia; Patients With Chemotherapy-Induced Thrombocytopenia; ITP - Immune Thrombocytopenia; Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors … | Dec 2028 |
| Novartis | Eltrombopag Thrombopoietin receptor agonist | MPL | Phase 2 | Myelodysplastic Syndromes | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Avatrombopag Thrombopoietin receptor agonist | MPL | Phase 2 | Immune Thrombocytopenia | – |
| Anhui Provincial Hospital | Lusutrombopag Thrombopoietin receptor agonist | MPL | Phase 2 | Thrombocytopenia | – |
| Renata | Eltrombopag Thrombopoietin receptor agonist | MPL | Phase 1 | Primary Immune Thrombocytopenia; Healthy; Hematological Neoplasms; ITP - Immune Thrombocytopenia … | – |
Primary Immune Thrombocytopenia (3) ITP - Immune Thrombocytopenia (3) Primary Immune Thrombocytopenia (ITP) (3) Chemotherapy-induced Thrombocytopenia (3) Immune Thrombocytopenia (3) Severe Aplastic Anemia (2) Persistent Isolated Chemotherapy-Induced Thrombocytopenia (2) Healthy (1) Hematological Neoplasms (1) Fanconi Anemia (1) Myelodysplastic Syndromes (1) Chemotherapy-Induced Thrombocytopenia (1)
small molecule (7)
Renata (1) Al-Mustansiriyah University (1) Novartis (1) Jiangsu HengRui Medicine (1) Amgen (1) Institute of Hematology & Blood Diseases Hospital, China (1) Anhui Provincial Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.